ArticlePulmonary circulation
Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe.
Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.Respiratory research · 2024Pooled it
- What is the difference between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension on phase-resolved functional lung MRI? A cross-sectional observational study.European radiology · 2026Observational
- Assessing the Impact of Time to Diagnosis and Treatment for Patients With Pulmonary Arterial Hypertension.Pulmonary circulation · 2025Article
- Pulmonary Hypertension: Let's Take Stock!Life (Basel, Switzerland) · 2025Review
- Chronic Thromboembolic Pulmonary Hypertension in Latvia: Epidemiological Insights and Diagnostic Challenges From 2024.Pulmonary circulation · 2025Article
- Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox.International journal of cardiology. Congenital heart disease · 2025Review
- Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE.Pulmonary circulation · 2024Article
- The Initial Experience of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension in Latvia.Medicina (Kaunas, Lithuania) · 2024Article
- Pulmonary Hypertension in Women.Methodist DeBakey cardiovascular journal · 2024Review
- Sex-biased TGFβ signalling in pulmonary arterial hypertension.Cardiovascular research · 2023Review
- Article
- Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019-2020.Medicina (Kaunas, Lithuania) · 2023Article
- Determinants of Severe Nocturnal Hypoxemia in Adults with Chronic Thromboembolic Pulmonary Hypertension and Sleep-Related Breathing Disorders.Journal of clinical medicine · 2023Article
- The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH.Journal of clinical medicine · 2023Article
- Pulmonary arterial hypertension incidence in Latvia in 2019.Pulmonary circulation · 2022Article
- Chronic Thromboembolic Pulmonary Hypertension: An Observational Study.Medicina (Kaunas, Lithuania) · 2022Observational
- Incidence and outcomes of pulmonary hypertension in the Ireland.BMJ open respiratory research · 2022Article
- Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).Pulmonary circulation · 2022Article
- A Retrospective Population-Based Survival Study of Idiopathic Pulmonary Arterial Hypertension in Korea.Journal of Korean medical science · 2022Article
- Chronic Thromboembolic Pulmonary Hypertension: An Update.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient registries are a valuable tool in the research of rare conditions such as pulmonary hypertension (PH). We report comprehensive hemodynamic and survival data of 174 patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), included in the prospective Latvian PH registry over a period of > 9 years. In total, 130 adult PAH patients (75%) and 44 adult CTEPH patients (25%) were enrolled. The median follow-up period was 33 months for PAH and 18 months for CTEPH, P = 0.001. Latvian CTEPH patients had significantly higher plasma levels of B-type natriuretic peptide, higher pulmonary vascular resistance, and lower cardiac index than Latvian PAH patients. Calculated incidence of PAH and CTEPH in Latvia in 2016 was 13.7 and 5.1 cases per million inhabitants, calculated prevalence was 45.7 and 15.7 cases per million inhabitants, respectively. Survival rates at one, three, and five years for PAH patients was 88.0%, 73.3%, and 58.1%, and 83.8%, 59.0%, and 44.2% for CTEPH patients, respectively. We compared our study results with data from European adult PH registries. Latvian PAH patients had the fourth lowest and CTEPH patients the lowest one-year survival rate among European adult PH registries. As most PH registries in Europe are small, yet with equivalent patient inclusion criteria, it would be desirable to combine these registries to produce more reliable and high-quality study results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.